Kymera Therapeutics, Inc. (KYMR)

Market Cap	6.94B +251.8%
Revenue (ttm)	39.21M -16.7%
Net Income	-311.35M
EPS	-3.69
Shares Out	81.64M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	399,731
Open	86.86
Previous Close	87.35
Day's Range	84.19 - 87.51
52-Week Range	20.25 - 103.00
Beta	2.29
Analysts	Strong Buy
Price Target	107.72 (+26.66%)
Earnings Date	May 8, 2026

About KYMR

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 21, 2020
• Employees: 238
• Stock Exchange: NASDAQ
• Ticker Symbol: KYMR
• Website: https://www.kymeratx.com

Financial Performance

In 2025, Kymera Therapeutics's revenue was $39.21 million, a decrease of -16.70% compared to the previous year's $47.07 million. Losses were -$311.35 million, 39.1% more than in 2024.

Analyst Summary

According to 26 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $107.72, which is an increase of 26.66% from the latest price.

Price Target

$107.72

(26.66% upside)

Analyst Consensus: Strong Buy